Premium
Cost‐effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study
Author(s) -
Hart Warren Mark,
RubioTerres Carlos,
Pajuelo Francisco,
Juanatey Jose R. González
Publication year - 2002
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(02)00087-9
Subject(s) - ramipril , medicine , heart failure , myocardial infarction , cost effectiveness , emergency medicine , intensive care medicine , clinical trial , cardiology , risk analysis (engineering) , blood pressure
Aims To estimate the cost‐effectiveness of adding ramipril to conventional treatment in patients with heart failure after myocardial infarction from the perspective of the Spanish National Health System. Methods and results A retrospective analysis of the AIRE study was made, using previously published data from the clinical trial combined with local Spanish resource and cost data. A typical rehospitalisation for a heart failure episode would last an average of 11.6 days with an average cost of €350.80 per day. The incremental cost of ramipril per life‐year gained in the baseline case was €1550.10 after 3.8 years of follow‐up. Sensitivity analysis showed that the basic conclusions were robust in spite of extreme variations in the values of the key parameters of the model. Conclusion The use of ramipril in addition to conventional treatment in heart failure patients after myocardial infarction is cost‐effective both according to currently accepted international standards of what constitutes a cost‐effective intervention and also indirectly by comparing the results with similar pharmaceutical products financed under the Spanish National Health System.